The disposition of subcutaneous injected C-razuprotafib (C-AKB-9778), a sulphamic acid phosphatase inhibitor, in nonclinical species and human.

The disposition of radioactivity following subcutaneous C-razuprotafib, a Tie2 activator, was explored in multiple species.The absorption and clearance of razuprotafib and total radioactivity in human plasma are rapid and pharmacokinetics support razuprotafib as primary circulating component. Radioactivity is distributed greater to human plasma than whole blood (B:P = 0.